Ozempic 'verdoving' claims: what the evidence actually says

What did @chanideleeuw_ actually say?

The caption does the heavy lifting here because the transcript is largely incoherent, likely a failed auto-transcription of a Dutch-language video. Based on the caption, the creator argues that Ozempic is "not a solution, it is an anesthetic," that it is facing €2 billion in lawsuits over side effects including gastroparesis, gallbladder problems, nausea, muscle breakdown, and vision loss, and most provocatively, that the drug "numbs your emotions and intuition." That last claim is the one worth scrutinizing hardest. The framing throughout is that semaglutide is a dangerous quick fix being sold as a miracle. The creator is clearly anti-GLP-1, and that bias shapes how every piece of evidence gets presented.

Does the science back this up?

Partially, but the creator oversimplifies significantly. The lawsuit claims and several side effects are real. The "emotional numbing" framing is where things get genuinely distorted.

The gastroparesis risk is documented. A 2023 study by Sodhi et al. in JAMA found that GLP-1 receptor agonists were associated with a significantly higher risk of gastroparesis compared to bupropion-naltrexone in patients without diabetes. That is a real finding. Gallbladder issues, including cholelithiasis, are listed in Novo Nordisk's prescribing information and supported by a 2022 meta-analysis by He et al. in EClinicalMedicine. The litigation is also real: multiple class-action lawsuits in the United States and Europe have cited gastroparesis and related gastrointestinal harms.

Vision loss is more complicated. A 2024 retrospective study by Hathaway et al. in JAMA Ophthalmology flagged a possible association between semaglutide and non-arteritic anterior ischemic optic neuropathy (NAION). The authors were cautious about causality. Associational does not mean proven, and the FDA has not updated its label on this basis alone.

Muscle loss is a legitimate concern. Studies including one by Wilding et al. (2021, NEJM) show that a portion of weight lost on semaglutide comes from lean mass, though resistance training appears to mitigate this.

What did they get wrong (or right)?

The creator gets credit for flagging gastroparesis and gallbladder risks, which are real and underreported in popular media. The lawsuit framing, while dramatic, is factually grounded in ongoing litigation.

Where they go off track is the "emotional numbing" claim. There is some emerging patient-reported evidence, and anecdotal reports to the FDA's MedWatch system, suggesting that some users on semaglutide experience blunted affect or reduced motivation. However, this has not been established in controlled clinical trials as a primary adverse effect. The mechanism the creator implies, that the drug deliberately or routinely suppresses emotions, is not supported by peer-reviewed evidence. GLP-1 receptors do exist in the brain and the drug does affect dopamine pathways, but calling this "anesthetizing your intuition" is a narrative leap, not a clinical conclusion.

Describing semaglutide as purely "a numbing agent" also ignores the substantial cardiovascular outcome data. The SELECT trial (Lincoff et al., 2023, NEJM) showed a 20% reduction in major cardiovascular events in overweight adults without diabetes. That is not nothing, and omitting it is a material distortion.

What should you actually know?

GLP-1 receptor agonists are not a miracle and they are not poison. They are a class of drugs with real, documented benefits for weight management and cardiovascular risk, and also real, documented risks that deserve honest conversation rather than either cheerleading or fearmongering.

The side effect profile is genuine. Nausea affects a large share of users, particularly at dose escalation. Gastroparesis risk appears elevated in some populations. Gallstone formation is a known complication, possibly linked to rapid weight loss rather than the drug itself. Muscle mass loss is a concern that clinicians increasingly address through protein intake and resistance training protocols.

The emotional blunting question is legitimately open. Some researchers are studying GLP-1's effects on reward pathways and mood. That research deserves to develop without being overstated in either direction. If you are experiencing mood changes on any GLP-1 medication, that is worth raising with your prescribing clinician, not diagnosing from a TikTok caption.

• Do not stop a prescribed medication based on social media content.
• Lawsuits reflect alleged harms, not proven causation.
• Side effect risk varies significantly based on dose, duration, and individual health profile.